TTD | Drug: D0NS7A

Drug General Information
Drug ID	D0NS7A
Former ID	DIB015089
Drug Name	APN-301
Synonyms	EMD-273063; Ch14.18-IL-2; Hu14.18-IL-2
Indication	Melanoma [ICD9: 172; ICD10:C43]		Phase 2	[522201]
Company	Apeiron biologics
Target and Pathway
Target(s)	Interleukin-2	Target Info	Modulator	[550261]
KEGG Pathway	Cytokine-cytokine receptor interaction
	PI3K-Akt signaling pathway
	Jak-STAT signaling pathway
	T cell receptor signaling pathway
	Intestinal immune network for IgA production
	Type I diabetes mellitus
	Chagas disease (American trypanosomiasis)
	Measles
	HTLV-I infection
	Autoimmune thyroid disease
	Inflammatory bowel disease (IBD)
	Allograft rejection
	Graft-versus-host disease
NetPath Pathway	IL-7 Signaling Pathway
	TCR Signaling Pathway
	TNFalpha Signaling Pathway
PANTHER Pathway	Inflammation mediated by chemokine and cytokine signaling pathway
PANTHER Pathway	Interleukin signaling pathway
Pathway Interaction Database	IL27-mediated signaling events
	IL12-mediated signaling events
	Calcineurin-regulated NFAT-dependent transcription in lymphocytes
	SHP2 signaling
	Regulation of Telomerase
	Glucocorticoid receptor regulatory network
	IL2-mediated signaling events
	IL2 signaling events mediated by PI3K
	AP-1 transcription factor network
	IL23-mediated signaling events
	IL2 signaling events mediated by STAT5
	Calcium signaling in the CD4+ TCR pathway
	Downstream signaling in na&#xef
	IL12 signaling mediated by STAT4
Reactome	GPVI-mediated activation cascade
	G beta:gamma signalling through PI3Kgamma
	Interleukin-2 signaling
	RAF/MAP kinase cascade
	Interleukin receptor SHC signaling
WikiPathways	Cytokines and Inflammatory Response
	IL-2 Signaling Pathway
	Inflammatory Response Pathway
	Aryl Hydrocarbon Receptor Pathway
	Interleukin-2 signaling
	T-Cell Receptor and Co-stimulatory Signaling
	Spinal Cord Injury
	Corticotropin-releasing hormone
	Allograft Rejection
	Arylhydrocarbon receptor (AhR) signaling pathway
	Interleukin-3, 5 and GM-CSF signaling
	Folate Metabolism
	IL-5 Signaling Pathway
References
Ref 522201	ClinicalTrials.gov (NCT00590824) Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma. U.S. National Institutes of Health.
Ref 550261	Clinical pipeline report, company report or official report of APEIRON Biologics.

Drug Information